Cocrystals are a prospective class of pharmaceutical products, in which it is possible to improve a number of pharmaceutically significant properties, such as solubility, fluidity, tabletability, using a strategy of crystalline engineering. Since only a small number of cocrystals have been brought into production so far, there is not much research on the scaling of cocrystal crystallization. In general, the development of the scaling of the crystallization process is a technological challenge. Scaling must ensure reproducibility, phase and chemical purity, good yield and certain crystal properties such as morphology and particle size. Challenges arise due to the stochastic nature of nucleation and the significant influence of equipment on crystallization results. This project will combine experimentally determined indicators of cocrystal stability and formation kinetics with numerical modelling using a particle balance model in combination with numerical hydrodynamics to develop a general methodology that allows the scaling of pharmaceutical cocrystal crystals.The aim of this study is to develop a numerical modelling-based methodology for the scaling of pharmaceutical cocrystal crystals. The obtained methodology would define the approach to the scaling of the modelling based crystallization applied to various cocrystals.Successful implementation of the project will contribute to the development of biomedicine, medical technology, biopharmaceuticals and biotechnology in the field of specialization defined by the Latvian Smart Specialization Strategy (RIS3). The results of the project will be used in the development of new methods of production of pharmaceutical cocrystals and in general will make the stage of crystallization scaling faster and more cost-effective, thus contributing to the transformation of the Latvian economy into higher value-added products and a productive innovation system, as well as to the change of export structure, encouraging the growth of sectors in which high value-added products and services exist or may arise.In order to achieve the objective of the project, an interdisciplinary study will be carried out, which includes applied research in the fields of chemistry, physics, computer science and information technology, medical and health sciences, as well as chemical engineering (Research and Development (FORD) classification codes 1.4, 1.3, 1.2, 3.1 and 2.4), specific to the subfields of physical chemistry, chemical engineering and numerical modelling.The project is non-economical and will be an independent study for the acquisition of broader knowledge and understanding (NACE code 72.19). The project activities are in line with the industrial research. The project will be implemented by a scientific institution (University of Latvia) in cooperation with the cooperation partner AS Olpha (part of the project 40%). Since the result of the project will be the method of pharmaceutical cocrystals scaling, the project as a whole will contribute to the development of the sector of economic activity Manufacture of basic pharmaceutical substances (NACE code 21.10).The scientific director of the project is associate professor Dr. Chem. The following activities will be carried out within the framework of the project: 1) research for acquisition of new knowledge and development of new technologies; 2) dissemination of research results, including publication of 4 scientific articles, presentations at 6 international conferences and informing the target group of the project; 3) protection of intellectual property rights and 4) actions to ensure communication and visual identity requirements.The results of the project will be: 1) 4 scientific articles published in the leading international databases (Scopus, WoS) indexed journals in the fields of crystalline engineering, chemical engineering and/or pharmaceutical sciences; 2) 1 scaled crystallization method for obtaining a pharmaceutically significant cocrystal, which will be commercialized as an intellectual property license agreement; 3) 1 patent application – method for obtaining the cocrystal of the active pharmaceutical ingredient, 4) 1 functional prototype – crystallisation reactor intended for optimally obtaining a selected pharmaceutical cocrystal based on modelling results (TRL4), 5) 1 complex. mathematical model for numerical modelling of the cocrystal crystallisation process, which will be registered as technology law – other intangible assets, 6) 6 presentations at various international conferences.Project duration 36 months (01.09.2025 – 31.08.2028). The total cost of the project is EUR 656 455.14, including ERDF funding of EUR 510 065.65. Keywords: crystallisation; pharmaceutical cocrystals, crystallization scaling, numerical modelling, particle balance model, numerical hydrodynamics.